Skip to content
RPG Life Sciences logo

RPG Life Sciences

RPGLIFE NSE
₹2,598.50 No trade today
P/E
35.98
View as Markdown
MCP
Close 4 Nov 2026 ₹2,598.50 +148.20 +6.05% 1Y
Start ₹2,450.30

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
25.70%
Debt to Equity
0.03
EPS (TTM)
₹72.22
Book Value
₹415.51
Market Cap
—
P/E (TTM)
35.98
P/B
6.25
ROE
19.30%
Dividend Yield
0.95%
EBITDA
₹173 Cr
52W High
₹3,127.80
52W Low
₹1,733.00
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

RPG Life Sciences peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
RPG Life Sciences (this company)
₹2,598.5035.98₹4,251 Cr6.250.95%19.30%25.70%₹734 Cr₹120 Cr
Median 8 companies₹2,048.6037.40₹1,25,337 Cr5.510.70%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 100/100

Category scores

Quality
59
Good
Returns, margins, earnings quality 22% weight
Valuation
45
Weak
Cheap vs sector & own history 24% weight
Growth
43
Weak
Sales & profit trajectory 9% weight
Financial Health
90
Strong
Solvency, leverage, coverage 9% weight
Momentum
44
Weak
Trend strength, vol-adjusted 12% weight
Ownership
60
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.8%

Weaknesses

3
  • Stock is trading at 7.68 times its book value
  • Debtor days have increased from 46.5 to 60.2 days.
  • Working capital days have increased from 44.6 days to 63.7 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1054
OscillatorsNeutral252
Moving AveragesStrong Bearish802

Key readings

RSI (14)
43.31
Neutral
MACD (12,26,9)
−54.29
Bearish
SMA (50)
2,772.27
Bearish
SMA (200)
2,377.50
Bullish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+9.76%
5Y+12.72%
3Y+11.34%
1Y+8.42%
TTM+11.87%

Net profit

Net profit growth by window
10Y+25.36%
5Y+23.52%
3Y+19.14%
1Y−37.16%
TTM−34.07%

Operating cash flow

Operating cash flow growth by window
10Y+5.43%
5Y−0.70%
3Y−14.94%
1Y−28.21%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+12.66 pp
5Y+2.65 pp
3Y+0.63 pp
1Y−3.76 pp
TTM−2.37 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹294 Cr
Mar 2018₹344 Cr
Mar 2019₹330 Cr
Mar 2020₹376 Cr
Mar 2021₹389 Cr
Mar 2022₹440 Cr
Mar 2023₹513 Cr
Mar 2024₹582 Cr
Mar 2025₹653 Cr
Mar 2026₹708 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹21.00 Cr
Mar 2018₹13.00 Cr
Mar 2019₹11.00 Cr
Mar 2020₹29.00 Cr
Mar 2021₹40.00 Cr
Mar 2022₹51.00 Cr
Mar 2023₹68.00 Cr
Mar 2024₹88.00 Cr
Mar 2025₹183 Cr
Mar 2026₹115 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹192 Cr +10.9% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk medium

RPG Life Sciences Ltd is a nearly debt-free healthcare company with a market cap of ₹4,574 Cr trading at a PE of 38.4x and PB of 7.59x. The company has delivered a 5-year profit CAGR of 22% and maintained ROE averaging 23% over five years, though recent working capital efficiency has deteriorated with debtor days rising from 46.5 to 60.2 days.

Bull Case 8
  • Company is almost debt-free, providing significant financial flexibility and low interest cost burden
  • Consistent 5-year ROE of 23% indicates strong capital efficiency and durable competitive advantages in its niche
  • Compounded profit growth of 22% over 5 years outpaces revenue growth of 13%, reflecting improving operating leverage and margin expansion
  • 10-year compounded profit CAGR of 25% demonstrates a long track record of sustained earnings growth
  • Stock has delivered a 3-year CAGR of 38% and 5-year CAGR of 40%, reflecting strong market confidence in the business trajectory
  • Healthy dividend payout ratio of 28.8% with a yield of 0.86% shows shareholder-friendly capital allocation despite being a growth company
  • TTM sales growth of 12% and profit growth of 13% indicate continued momentum in the most recent period
  • 10-year compounded sales CAGR of 10% shows the company has consistently grown its topline across business cycles
Bear Case 7
  • PE of 38.4x is elevated relative to broader pharma sector averages, pricing in significant future growth expectations
  • Debtor days increased from 46.5 to 60.2 days, suggesting deteriorating collection efficiency or channel stuffing risk
  • Working capital days expanded from 44.6 to 63.7 days, indicating the business is requiring more capital to fund operations
  • Last year ROE declined to 19% from a 3-year average of 23%, signaling potential moderation in return profile
  • Market cap of ₹4,574 Cr with a small-to-mid cap profile carries higher liquidity risk and volatility compared to large-cap pharma peers
  • TTM profit growth of 13% is below the 5-year CAGR of 22%, suggesting a possible deceleration in earnings momentum
  • 3-year sales CAGR of 11% lags the 5-year profit CAGR of 22%, raising questions about sustainability of margin expansion

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

94d ago

TL;DR: RPG Life Sciences is executing well with 16% YoY profit growth and a strategic API business spinoff targeting ₹700 crore in fresh investment. The ₹24 dividend and new product partnership signal management confidence. Key leadership departures (VP Sales, Independent Director) are routine but worth monitoring for succession clarity. The trend is improving with growth investments and strong quarterly results pointing to continued momentum.

Positives 4
  • API spinoff eyes ₹700 cr growth Jul 29

    Board approved slump sale of API business to a wholly owned subsidiary for ₹33.55 crore, aiming to raise up to ₹700 crore from investors for organic and inorganic growth in the API segment.

  • Q1FY26 profit up 16% YoY Jul 29

    Standalone net profit rose 16% YoY to ₹305.7 lakh for Q1FY26, with revenue growing 16-18.5% to ₹195.7 crore driven by pharmaceutical operations.

  • ₹24 per share dividend declared Jul 23

    Shareholders approved a ₹24 dividend per share and reappointed key directors at the 19th AGM held on July 23, 2026.

Neutral 2
  • VP Sales & Marketing retires Aug 1

    Samir Rane, Vice President of Sales & Marketing (Main Division), retired on July 31, 2026 due to superannuation with no immediate successor named.

  • Independent Director exits board Jul 27

    Ms. Zahabiya Khorakiwala ceased as Independent Director on July 26, 2026 after completing her second consecutive five-year term.

Quarterly Results

₹ Cr
RPGLIFE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
148
154
154
127
165
172
173
143
169
182
180
177
196
193
Expenses
116
116
116
106
126
126
124
118
133
143
140
144
152
161
Operating Profit
32
37
38
21
39
46
49
25
35
39
40
33
44
33
OPM %
22%
24%
25%
16%
24%
27%
28%
18%
21%
21%
22%
19%
22%
17%
Other Income
2
2
2
2
2
−25
3
115
5
16
−5
13
4
4
Interest
0
0
0
0
0
0
0
0
0
0
0
0
1
1
Depreciation
4
4
4
4
5
5
5
5
5
5
5
6
6
6
PBT
30
35
36
18
36
15
47
135
35
49
29
40
41
30
Tax %
26%
26%
26%
25%
26%
72%
26%
13%
26%
25%
24%
26%
26%
23%
Net Profit
22
26
26
13
27
4
35
117
26
37
22
30
31
23
EPS (₹)
13.36
15.64
16
8.01
16.18
2.54
21.12
70.95
15.9
22.28
13.38
18.08
18.48
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
RPGLIFE profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
242
279
294
344
330
376
389
440
513
582
653
708
734
Expenses
228
256
274
306
296
315
318
353
408
453
493
560
579
Operating Profit
14
23
20
38
34
60
71
87
104
129
161
148
155
OPM %
6%
8%
7%
11%
10%
16%
18%
20%
20%
22%
25%
21%
21%
Other Income
1
1
18
1
1
−5
1
3
4
7
95
29
28
Interest
3
2
4
5
5
3
2
1
1
1
0.62
2
1
Depreciation
11
10
11
14
15
16
16
16
16
17
21
21
22
PBT
1
12
23
20
15
36
54
73
92
118
233
154
160
Tax %
0%
0%
10%
34%
28%
20%
25%
30%
26%
26%
21%
25%
—
Net Profit
1
12
21
13
11
29
40
51
68
88
183
115
119
EPS (₹)
0.6
7.03
12.7
8.13
6.54
17.54
24.19
31.13
40.9
53
111
69.64
72.22
Div. Payout %
132%
23%
22%
30%
37%
23%
30%
31%
29%
30%
22%
34%
—

Balance Sheet

₹ Cr
RPGLIFE balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
13
13
13
13
13
13
Reserves
112
120
134
142
147
163
203
243
294
362
517
592
Borrowings
33
23
45
54
36
12
2
1
0
0
0
20
Other Liabilities
39
49
55
82
54
78
85
88
112
138
127
168
Total Liabilities
197
205
247
291
251
267
303
345
419
513
658
793
Fixed Assets
105
109
137
131
128
123
113
104
124
114
172
197
CWIP
1
2
2
9
17
10
12
31
25
96
16
23
Investments
0
0
0
0
0
0
0
0
58
91
127
120
Other Assets
92
94
108
152
106
134
178
210
211
212
343
454
Total Assets
197
205
247
291
251
267
303
345
419
513
658
793

Cash Flow

₹ Cr
RPGLIFE cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−2
33
7
15
46
50
58
65
91
94
78
56
Investing
−10
−15
−30
−16
−19
−11
−8
−35
−106
−79
−42
51
Financing
12
−18
23
0
−26
−39
−10
−14
−17
−20
−27
−21
Net Cash Flow
0
0
1
−1
0
0
40
17
−32
−5
9
87
Free Cash Flow
−12
18
−48
−1
26
39
50
41
58
25
151
−9
CFO/EBITDA
14
150
58
48
144
94
94
96
111
96
81
63

Ratios

RPGLIFE financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
48
49
72
43
62
54
27
27
31
48
60
Inventory Days
149
156
163
171
136
133
162
214
203
200
159
179
Days Payable
109
135
102
165
83
127
132
117
138
140
135
141
Cash Conversion Cycle
101
70
110
78
96
68
84
124
91
90
72
99
Working Capital Days
27
26
20
22
20
41
52
47
33
25
45
64
ROCE %
2%
9%
10%
13%
10%
23%
27%
31%
33%
35%
33%
26%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view RPG Life Sciences insights

65 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.95%
  • Public 13.11%
  • DIIs 9.93%
  • Others 3.14%
  • FIIs 0.87%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Documents

Frequently Asked Questions about RPG Life Sciences

What does RPG Life Sciences Ltd do?
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients
Where is RPG Life Sciences Ltd (RPGLIFE) listed?
RPG Life Sciences Ltd trades as RPGLIFE on the NSE and under code 532983 on the BSE.
Which sector does RPG Life Sciences Ltd belong to?
RPG Life Sciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of RPG Life Sciences Ltd?
RPG Life Sciences Ltd trades at a PE ratio of 35.98 as of 4 Nov 2026, on earnings per share of ₹72.22, against a book value of ₹415.51 per share.
What is the 52-week high and low of RPG Life Sciences Ltd?
Over the last 52 weeks RPG Life Sciences Ltd has traded between ₹1,733 and ₹3,127.8 as of 4 Nov 2026.
Does RPG Life Sciences Ltd pay dividends?
RPG Life Sciences Ltd has a dividend yield of 0.95%.
What is the Return on Equity (ROE) of RPG Life Sciences Ltd?
RPG Life Sciences Ltd reported a return on equity of 19.30%. Its debt-to-equity ratio is 0.03.

Company Information

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients

Website rpglifesciences.com
CEO Mr. Ashok Nair
Employees 1,331
Listed 10 Jun 2008
Face Value ₹8

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/RPGLIFE.md for RPG Life Sciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month